Biohaven Pharmaceutical Holding Company Ltd. (BHVN), which disappointed investors early this month, following negative results from its phase III trial of Troriluzole in Generalized Anxiety Disorder, has two more catalysts to watch out for this quarter.
from RTT - Biotech https://ift.tt/32tNSNP
via IFTTT
No comments:
Post a Comment